Eli Lilly: to collaborate with Junshi on Covid treatments

(CercleFinance.com) - Eli Lilly said that it has entered into an agreement with China's Junshi Biosciences to develop therapeutic antibodies for the prevention and treatment of Covid-19.


At the beginning of the outbreak, Junshi launched one of the industry's first R&D efforts aimed at discovering therapies to combat the virus.

The Chinese biopharmaceutical company has now engineered multiple neutralizing antibodies, with the lead asset set to enter clinical testing in the second quarter, it said.

Lilly plans to accelerate the clinical development of these SARS-CoV-2 antibodies as part of an exclusive license to conduct clinical development, manufacturing and distribution of products outside of Greater China.

Junshi will maintain all rights in Greater China.

Copyright (c) 2020 CercleFinance.com. All rights reserved.